• Mobilizing the Immune System

    A clinical-stage biopharmaceutical company leveraging from its multiple drug development platforms to treat patients with inflammatory diseases, viral infections, and cancer.
  • ABX464

    Fighting Inflammatory Diseases

    Abivax’s lead candidate ABX464, a potent anti-inflammatory agent, is being tested in a Phase 2b clinical trial for its potential to bring clinical benefit to patients with ulcerative colitis, and potentially other inflammatory indications.
  • ABX464

    Developing a Functional Cure for HIV

    ABX464 is a Phase 2 candidate designed to functionally cure HIV by reducing the viral reservoir and is the first ever drug candidate to demonstrate this reduction in patients.
  • ABX196

    Tackling Cancer

    A small molecule agonist of invariant Natural Killer T-Cells (iNKT) is currently being tested in a Phase 1/2 clinical trial for treatment of hepatocellular carcinoma (HCC).

About Us

Abivax is developing therapies that stimulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, HIV, and liver cancer.

Its lead clinical candidate, ABX464, has demonstrated the potential to treat inflammatory diseases and to reduce the viral reservoir in HIV.

Learn More View our Corporate Presentation

Pipeline

With five programs in clinical testing, a trial in Crohn’s disease to start and three projects in research and preclinical development, Abivax’s pipeline is strong and diversified, addressing many unmet needs.

Clinical Programs

  • ABX464 COVID-19

    ABX464 is an oral, first-in-class, small molecule that has been shown to inhibit the replication of the HIV virus and to have a sustainable anti-inflammatory effect in patients suffering from ulcerative colitis along with tissue repair properties. In addition, new in vitro data also have shown the ability of ABX464 to inhibit the replication of SARS-CoV-2 (COVID-19). With a potential triple effect that includes 1) inhibition of the SARS-CoV-2 virus replication, 2) prevention and treatment of the acute respiratory distress syndrome (ARDS) caused by hyperinflammation, as well as 3) limit longer-term pulmonary dysfunction due to resulting tissue damage in the lungs, ABX464 could be a promising candidate for the treatment of the COVID-19 disease, especially in its severe form. Therefore, a Phase 2b/3 study with ABX464 in 1,034 patients with COVID-19 is being conducted in Europe and Latin America to assess whether the drug candidate can prevent the cytokine storm and ARDS in these patients.

    Read More
  • ABX464 UC

    ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in a Phase 2a clinical trial, ABX464-101, to treat ulcerative colitis (UC). Patients who completed the induction study had the option to roll over into a 12-month open-label extension study, ABX464-102, in which 22 out of 23 eligible patients were enrolled.

    Read More
  • ABX464 Crohn’s Disease

    ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory efficacy in a completed Phase 2a induction study as well as a 24-month maintenance study in patients with moderate-to-severe ulcerative colitis (UC).
    Due the clinical similarities of Crohn’s disease (CD) and UC, and the predictability of the DSS model for both UC and CD, several key opinion leaders (KOLs) are confident that ABX464 will also show beneficial effects in patients suffering from CD.

    Read More
  • ABX464 Rheumatoid Arthritis

    ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in a completed Phase 2a induction study as well as a 12-month maintenance study in patients with moderate-to-severe ulcerative colitis (UC). In addition to the clinical observations in UC patients, Abivax generated promising pre-clinical data from collagen-induced arthritis animal models.

    Read More
  • ABX464 HIV

    ABX464 is an oral, first-in-class, novel, small molecule inhibiting HIV replication through an entirely new mechanism of action. For the first time in the treatment of HIV, this molecule could reduce or eliminate the viral reservoirs, and thus potentially deliver a long-lasting virological suppression in HIV-patients.

    Read More
  • ABX196 HCC

    ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer models.

    Read More

Science

Based on innovative research driven by the idea of stimulating the body’s natural immune system mechanisms to cure diseases.

Read More

News & Events

View More

Investors

Abivax SA has been listed on the Paris stock exchange since June 26, 2015.

View More

Symbol

ABVX

USER NOTIFICATION

The information on the following pages is restricted and is not for release, publication or distribution in or into Australia, Canada, Japan or the United States.

The information contained herein is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States, Canada, Japan or Australia, and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any shares or other securities of Abivax S.A. in the United States, Canada, Japan or Australia. The shares of Abivax S.A. referred to on this website have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. None of the information contained on the pages that follow nor any copy thereof may be taken or transmitted in or into the United States or distributed, directly or indirectly, in or into the United States. Failure to comply with this directive may result in a violation of the Securities Act.

All persons residing outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained. Abivax S.A. assumes no responsibility if there is a violation of applicable law and regulations by any person.

I certify that:

(1) I am an investor who customarily invests, or which has invested more than EUR 1 million in the last 24 months in, in the pharmaceutical sector or in growth securities that are listed on a regulated market or multilateral trading facility (such as, Euronext Growth), considered as “Community SMEs” within the meaning of Annex I to European Commission Regulation n°651/2014 of June 17, 2014,

And

(2) I am a resident of and physically present in a Member State of the European Economic Area or the United Kingdom, which is subject to the provisions of Regulation (EU) 2017/1129 of the European Parliament of the Council of June 14, 2017 (the “Prospectus Regulation”), and I am a qualified investor as defined in the Prospectus Regulation,

And

(3) I am not a resident of, or physically present in, the United States, Canada, Japan or Australia.